GWPH News and Press, GW Pharmaceuticals Plc From 05/07/19

Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...

Bridgeline Digital (NASDAQ: BLIN ) +37%  on announcing OrchestraCMS multi-year license renewal with global biopharmaceutical company. More news on: Bridgeline Digital, Inc., Akorn, Inc., Akoustis Technologies, Inc., Stocks on the move, Read more ...

GW Pharmaceuticals PLC (GWPH) Q1 2019 Results Conference Call May 06, 2019 04:30 PM ET Company Participants Steve Schultz - VP, IR Justin Gover - CEO Julian Gangolli - President, North America Darren Cline - U.S. Chief Commercial Officer Chris Tovey - COO Dr. Volker Knapper...

GW Pharmaceuticals (NASDAQ: GWPH ) is up  4%  after hours on its Q1 beat and on a successful Phase 3 clinical trial evaluating Epidiolex (cannabidiol) in patients with a rare and severe type of childhood epilepsy called tuberous sclerosis complex (TSC). More news on: GW Pharm...

GW Pharmaceuticals (NASDAQ: GWPH ) Q1 results ($M): Revenues: 39.2 (+999%); U.S. Epidiolex sales: 33.5. More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

GW Pharmaceuticals (NASDAQ: GWPH ): Q1 GAAP EPS of -$0.14 beats by $0.07 . Revenue of $39.25M (+1191.1% Y/Y) beats by $23.31M . Shares +3.2% . Press Release More news on: GW Pharmaceuticals plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news,

- Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 -  CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc...

- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30 p.m. EDT - CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the C...

The "why" behind the articles I write about trading is to help others see through the array of articles and opinions of what someone should be invested in. If I meet my objectives, what I have to say will be done with clarify and simple language. Source: Fidelity.com Using an Exchanged T...

Putting the cart before the horse The typical course of drug R&D goes something like this: a druggable target is identified early discovery efforts are launched a lead drug candidate is selected preclinical studies are conducted an IND is filed PhI, PhII and PhIII trials ar...